AbbVie Submits Regulatory Applications To FDA And EMA For Risankizumab In Ulcerative Colitis
Portfolio Pulse from Benzinga Newsdesk
AbbVie has submitted regulatory applications to the FDA and EMA for its drug Risankizumab, used in the treatment of ulcerative colitis. The submissions are backed by two Phase 3 clinical trials demonstrating the drug's effectiveness and safety. Risankizumab is currently approved by the FDA and EMA for Crohn's disease, psoriatic arthritis, and psoriasis.
August 28, 2023 | 12:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie's submission of regulatory applications for Risankizumab could potentially expand the drug's market, positively impacting the company's revenues if approved.
The news directly pertains to AbbVie and its drug Risankizumab. If the drug is approved for the treatment of ulcerative colitis, it could potentially increase the company's revenues by expanding the drug's market. The importance is high as it relates to a potential new revenue stream, and the confidence is high as the applications are backed by successful Phase 3 trials.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100